Brief: DexTech Gets Positive Results Regarding Multiple Myeloma
Feb 2 (Reuters) - DexTech Medical AB DEXTECH.TE :
* SAID ON MONDAY IT RECEIVES POSITIVE RESULTS REGARDING
MULTIPLE
MYELOMA
* SEES OSTEODEX AS VERY PROMISING FOR THE TREATMENT OF MM
* OBSERVED CELL KILLING EFFECT IS SUPERIOR TO THE COMPARED
SUBSTANCE, MELPHALAN, WHICH IS A STANDARD DRUG IN THE TREATMENT
OF MM
Source text for Eikon: urn:newsml:reuters.com:*:nWkr8pPrT
Further company coverage: DEXTECH.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))
Recent news on Dextech Medical AB
See all newsSwedish drug developer DexTech's Q4 operating loss widens; reports positive patient outcomes
Brief: DexTech Q4 Operating Profit SEK -1.9 Million
Sweden's DexTech Q3 loss widens, OsteoDex drug study shows favorable safety profile
Brief: DexTech Q3 Operating Profit SEK -1.7 Million
Brief: DexTech Q4 Operating Profit SEK -1.6 Million